ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon Print
Business deals

Ex-Takeda chairman comes out against Shire purchase

$62bn megadeal faces shareholder votes next week

Vitamins made by Shire. Takeda plans to buy the Irish drugmaker for $62 billion and has received approval from antitrust authorities in China, Japan, the U.S. and Europe.   © Reuters

TOKYO -- A Takeda Pharmaceutical former chairman credited with the company's rapid growth has expressed his opposition to Takeda's $62 billion acquisition of Irish drugmaker Shire, breaking a long silence.

Mergers and acquisitions are necessary in the pharmaceutical industry, "but the Shire deal's risk is high," Kunio Takeda told Nikkei through a representative.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

Discover the all new Nikkei Asia app

  • Take your reading anywhere with offline reading functions
  • Never miss a story with breaking news alerts
  • Customize your reading experience

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more